Cboe UK GBp

Hikma Pharmaceuticals PLC (HIKL.XC)

Compare
1,902.00 +6.50 (+0.34%)
At close: October 11 at 4:28 PM GMT+1
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
2,875,000.00
2,875,000.00
2,517,000.00
2,553,000.00
2,341,000.00
--
Cost of Revenue
1,485,000.00
1,485,000.00
1,279,000.00
1,252,000.00
1,140,000.00
--
Gross Profit
1,390,000.00
1,390,000.00
1,238,000.00
1,301,000.00
1,201,000.00
--
Operating Expense
786,000.00
786,000.00
756,000.00
704,000.00
641,000.00
--
Operating Income
604,000.00
604,000.00
482,000.00
597,000.00
560,000.00
--
Net Non Operating Interest Income Expense
-80,000.00
-80,000.00
-67,000.00
-39,000.00
-22,000.00
--
Pretax Income
281,000.00
281,000.00
233,000.00
544,000.00
558,000.00
--
Tax Provision
89,000.00
89,000.00
42,000.00
124,000.00
128,000.00
--
Net Income Common Stockholders
190,000.00
190,000.00
188,000.00
421,000.00
431,000.00
--
Diluted NI Available to Com Stockholders
190,000.00
190,000.00
188,000.00
421,000.00
431,000.00
--
Basic EPS
0.86
0.86
0.84
1.82
1.83
--
Diluted EPS
0.85
0.85
0.84
1.81
1.81
--
Basic Average Shares
220,862.10
220,862.10
223,728.47
231,000.00
236,000.00
--
Diluted Average Shares
222,368.71
222,368.71
224,908.81
233,000.00
238,000.00
--
Total Operating Income as Reported
367,000.00
367,000.00
282,000.00
582,000.00
579,000.00
--
Total Expenses
2,271,000.00
2,271,000.00
2,035,000.00
1,956,000.00
1,781,000.00
--
Net Income from Continuing & Discontinued Operation
190,000.00
190,000.00
188,000.00
421,000.00
431,000.00
--
Normalized Income
375,094.00
375,094.00
309,985.00
404,788.00
392,450.00
--
Interest Income
7,000.00
7,000.00
3,000.00
1,000.00
7,000.00
--
Interest Expense
73,000.00
73,000.00
59,000.00
56,000.00
56,000.00
--
Net Interest Income
-80,000.00
-80,000.00
-67,000.00
-39,000.00
-22,000.00
--
EBIT
354,000.00
354,000.00
292,000.00
600,000.00
614,000.00
--
EBITDA
552,000.00
552,000.00
485,000.00
744,000.00
705,000.00
--
Reconciled Cost of Revenue
1,485,000.00
1,485,000.00
1,279,000.00
1,252,000.00
1,140,000.00
--
Reconciled Depreciation
198,000.00
198,000.00
193,000.00
144,000.00
91,000.00
--
Net Income from Continuing Operation Net Minority Interest
190,000.00
190,000.00
188,000.00
421,000.00
431,000.00
--
Total Unusual Items Excluding Goodwill
-234,000.00
-234,000.00
-155,000.00
21,000.00
50,000.00
--
Total Unusual Items
-234,000.00
-234,000.00
-155,000.00
21,000.00
50,000.00
--
Normalized EBITDA
786,000.00
786,000.00
640,000.00
723,000.00
655,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-48,906.00
-48,906.00
-33,015.00
4,788.00
11,450.00
--
12/31/2019 - 1/30/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade